387 related articles for article (PubMed ID: 32048058)
21. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
Atkins MB; Tannir NM
Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
23. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Biró K; Küronya Z
Magy Onkol; 2010 Dec; 54(4):369-76. PubMed ID: 21163768
[TBL] [Abstract][Full Text] [Related]
24. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
Iisager L; Ahrenfeldt J; Donskov F; Ljungberg B; Bex A; Lund L; Lyskjær I; Fristrup N
BMC Cancer; 2024 Feb; 24(1):260. PubMed ID: 38402173
[TBL] [Abstract][Full Text] [Related]
25. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
26. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
27. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
Li J; Chen B; Cao D
Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
[No Abstract] [Full Text] [Related]
28. Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.
Das A; Shapiro DD; Craig JK; Abel EJ
Nat Rev Urol; 2023 Nov; 20(11):654-668. PubMed ID: 37400492
[TBL] [Abstract][Full Text] [Related]
29. Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma.
Reimers MA; Figenshau RS; Kim EH; Tucker J; Kasten N; Khan AS; Hanneken JM; Smith ZL; Hsieh JJ
Clin Genitourin Cancer; 2020 Oct; 18(5):361-366. PubMed ID: 32417157
[TBL] [Abstract][Full Text] [Related]
30. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Hara T; Miyake H; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):363-369. PubMed ID: 28169111
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.
Bedke J; Gouttefangeas C; Singh-Jasuja H; Stevanović S; Behnes CL; Stenzl A
World J Urol; 2014 Feb; 32(1):31-8. PubMed ID: 23404195
[TBL] [Abstract][Full Text] [Related]
32. Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.
Tenold M; Ravi P; Kumar M; Bowman A; Hammers H; Choueiri TK; Lara PN
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239988
[TBL] [Abstract][Full Text] [Related]
33. [Systemic therapy for metastatic renal cell carcinoma].
Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
[TBL] [Abstract][Full Text] [Related]
34. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
35. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
36. [Metastatic renal cell carcinoma: primary and follow-up treatment].
Steiner T; Mickisch GH
Urologe A; 2013 Nov; 52(11):1529-30, 1532-3. PubMed ID: 24170300
[TBL] [Abstract][Full Text] [Related]
37. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
39. Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.
Pourmir I; Noel J; Simonaggio A; Oudard S; Vano YA
World J Urol; 2021 May; 39(5):1377-1385. PubMed ID: 33386948
[TBL] [Abstract][Full Text] [Related]
40. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
